Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 4Terminated 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 25Neoplasm Metastasis 5Breast Neoplasms 5Prostatic Neoplasms, Castration-Resistant 4Pancreatic Neoplasms 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Prostate Cancer Metastatic 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Carcinoma, Renal Cell 2Bulbo-Spinal Atrophy, X-Linked 2Urinary Bladder Neoplasms 1Thrombocytosis 1Solid Tumours 1Small Cell Lung Carcinoma 1Prostate Adenocarcinoma 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Preference 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms, Squamous Cell 1NSCLC Harboring NRG1 Fusion 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Multiple Myeloma 1Metastatic Castration Resistant Prostate Cancer 1Metastatic Castrate-Resistant Prostate Cancer 1

Interventions

enzalutamide 2cabazitaxel 1Prednisone 1Positron Emission Tomography Computed Tomography 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Prostate Cancer Metastatic × enzalutamide × Clear all
NCT03850795 2024-08-19

HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Hinova Pharmaceuticals USA, Inc.

Phase 3 Terminated
104 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT02379390 2019-06-21

PRIMCAB

Sanofi

Phase 2 Terminated
8 enrolled 8 charts
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡